Novel quantitative immunohistochemical analysis for evaluating PD-L1 expression with phosphor-integrated dots for predicting the efficacy of patients with cancer treated with immune checkpoint inhibitors.

Saved in:
Bibliographic Details
Title: Novel quantitative immunohistochemical analysis for evaluating PD-L1 expression with phosphor-integrated dots for predicting the efficacy of patients with cancer treated with immune checkpoint inhibitors.
Authors: Ohkuma R; Division of Medical Oncology, Department of Medicine, School of Medicine, Showa University, Tokyo, Japan.; Department of Clinical Diagnostic Oncology, Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, Tokyo, Japan., Miura S; Department of Pathology, Showa University School of Medicine, Tokyo, Japan., Muto S; Department of Chest Surgery, School of Medicine, Fukushima Medical University, Fukushima, Japan., Toyomasu Y; Department of Digestive Tract and General Surgery, Saitama Medical Center, Saitama Medical University, Saitama, Japan., Fujimoto Y; Division of Medical Oncology, Department of Medicine, School of Medicine, Showa University, Tokyo, Japan.; Department of Clinical Diagnostic Oncology, Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, Tokyo, Japan.; Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, Tokyo, Japan., Ieguchi K; Department of Clinical Diagnostic Oncology, Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, Tokyo, Japan.; Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, Tokyo, Japan., Onishi N; Department of Clinical Diagnostic Oncology, Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, Tokyo, Japan.; Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, Tokyo, Japan., Shimizu T; Department of Clinical Diagnostic Oncology, Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, Tokyo, Japan.; Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, Tokyo, Japan., Watanabe M; Department of Clinical Diagnostic Oncology, Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, Tokyo, Japan.; Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, Tokyo, Japan.; Department of Pharmacology, School of Medicine, Showa University, Tokyo, Japan.; Pharmacological Research Center, Showa University, Tokyo, Japan., Takayanagi D; Division of Medical Oncology, Department of Medicine, School of Medicine, Showa University, Tokyo, Japan.; Department of Clinical Diagnostic Oncology, Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, Tokyo, Japan.; Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, Tokyo, Japan., Goshima T; Division of Medical Oncology, Department of Medicine, School of Medicine, Showa University, Tokyo, Japan.; Department of Clinical Diagnostic Oncology, Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, Tokyo, Japan.; Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, Tokyo, Japan., Horiike A; Division of Medical Oncology, Department of Medicine, School of Medicine, Showa University, Tokyo, Japan., Hamada K; Department of Chest Surgery, School of Medicine, Fukushima Medical University, Fukushima, Japan., Ariizumi H; Division of Medical Oncology, Department of Medicine, School of Medicine, Showa University, Tokyo, Japan., Shimokawa M; Division of Medical Oncology, Department of Medicine, School of Medicine, Showa University, Tokyo, Japan., Hirasawa Y; Division of Medical Oncology, Department of Medicine, School of Medicine, Showa University, Tokyo, Japan., Ishiguro T; Division of Medical Oncology, Department of Medicine, School of Medicine, Showa University, Tokyo, Japan., Suzuki R; Division of Medical Oncology, Department of Medicine, School of Medicine, Showa University, Tokyo, Japan., Iriguchi N; Division of Medical Oncology, Department of Medicine, School of Medicine, Showa University, Tokyo, Japan., Tsurui T; Division of Medical Oncology, Department of Medicine, School of Medicine, Showa University, Tokyo, Japan.; Department of Pharmacology, School of Medicine, Showa University, Tokyo, Japan.; Pharmacological Research Center, Showa University, Tokyo, Japan., Mura E; Division of Medical Oncology, Department of Medicine, School of Medicine, Showa University, Tokyo, Japan., Takenoshita S; Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, Tokyo, Japan., Numajiri K; Department of General Surgical Science, Graduate School of Medicine, Gunma University, Gunma, Japan., Okabe N; Department of Chest Surgery, School of Medicine, Fukushima Medical University, Fukushima, Japan., Yoshimura K; Division of Medical Oncology, Department of Medicine, School of Medicine, Showa University, Tokyo, Japan.; Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, Tokyo, Japan.; Department of Clinical Immuno Oncology, Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, Tokyo, Japan., Tsuji M; Pharmacological Research Center, Showa University, Tokyo, Japan., Kiuchi Y; Department of Pharmacology, School of Medicine, Showa University, Tokyo, Japan.; Pharmacological Research Center, Showa University, Tokyo, Japan., Yajima T; Department of General Thoracic Surgery, Faculty of Medicine, Kagawa University, Kagawa, Japan., Ishida H; Department of Digestive Tract and General Surgery, Saitama Medical Center, Saitama Medical University, Saitama, Japan., Suzuki H; Department of Chest Surgery, School of Medicine, Fukushima Medical University, Fukushima, Japan., Yamochi T; Department of Pathology, Showa University School of Medicine, Tokyo, Japan., Kobayashi S; Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, Tokyo, Japan., Tsunoda T; Division of Medical Oncology, Department of Medicine, School of Medicine, Showa University, Tokyo, Japan., Wada S; Division of Medical Oncology, Department of Medicine, School of Medicine, Showa University, Tokyo, Japan.; Department of Clinical Diagnostic Oncology, Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, Tokyo, Japan.; Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, Tokyo, Japan.; Department of Pharmacology, School of Medicine, Showa University, Tokyo, Japan.; Pharmacological Research Center, Showa University, Tokyo, Japan.
Source: Frontiers in immunology [Front Immunol] 2023 Sep 18; Vol. 14, pp. 1260492. Date of Electronic Publication: 2023 Sep 18 (Print Publication: 2023).
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101560960 Publication Model: eCollection Cited Medium: Internet ISSN: 1664-3224 (Electronic) Linking ISSN: 16643224 NLM ISO Abbreviation: Front Immunol Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1664-3224
DOI:10.3389/fimmu.2023.1260492